The use of ramukirumab in the treatment of metastatic gastric cancer in real clinical practice
- Авторлар: Belyak N.P.1,2, Kutukova S.I1,3, Orlova R.V1,2, Zhukova N.V1,2, Erdniev S.P1, Zorina E.Y.1, Avramenko I.V1, Antimonik N.Y.1, Popova N.V1, Ivanova A.K1, Androsova A.V1
-
Мекемелер:
- City Clinical Oncology Dispensary
- St. Petersburg State University
- Pavlov First St. Petersburg State Medical University
- Шығарылым: Том 26, № 7 (2019)
- Беттер: 38-42
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312205
- DOI: https://doi.org/10.18565/pharmateca.2019.7.38-42
- ID: 312205
Дәйексөз келтіру
Аннотация
Толық мәтін
Авторлар туралы
Nataliya Belyak
City Clinical Oncology Dispensary; St. Petersburg State University
Email: dmpb@mail.ru
PhD, Oncologist, Chemotherapy Department (№ 11), City Clinical Oncology Dispensary; Teaching Assistant at the Department of Oncology 56, Veteranov Avenue, St. Petersburg 198255, Russian Federation
S. Kutukova
City Clinical Oncology Dispensary; Pavlov First St. Petersburg State Medical UniversitySt. Petersburg, Russia
R. Orlova
City Clinical Oncology Dispensary; St. Petersburg State UniversitySt. Petersburg, Russia
N. Zhukova
City Clinical Oncology Dispensary; St. Petersburg State UniversitySt. Petersburg, Russia
S. Erdniev
City Clinical Oncology DispensarySt. Petersburg, Russia
E. Zorina
City Clinical Oncology DispensarySt. Petersburg, Russia
I. Avramenko
City Clinical Oncology DispensarySt. Petersburg, Russia
N. Antimonik
City Clinical Oncology DispensarySt. Petersburg, Russia
N. Popova
City Clinical Oncology DispensarySt. Petersburg, Russia
A. Ivanova
City Clinical Oncology DispensarySt. Petersburg, Russia
A. Androsova
City Clinical Oncology DispensarySt. Petersburg, Russia
Әдебиет тізімі
- Van Cutsem E., Sagaert X., Topal B., et al. Gastric cancer. Lancet. 2016;388:2654-64. doi: 10.1016/S0140-6736(16)30354-3.
- Wagner A.D., Unverzagt S., Grothe W., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064. doi: 10.1002/14651858.CD004064.pub3.
- Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97. doi: 10.1016/S0140-6736(10)61121-X.
- Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968-76. doi: 10.1200/JCO.2011.36.2236.
- Shah M.A., Bang Y.J., Lordick F., et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA. Oncol. 2016.
- Lordick F., Kang Y.K., Chung H.C., et al. Arbeitsgemeinschaft Internistische Onkologie, EXPAND investigators. capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open label phase 3 trial. Lancet. Oncol. 2013;14:490-99. Doi:10.1016/ S1470-2045(13)70102-5.
- Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673-84. Doi: 10.1136/ gutjnl-2011-301839. Epub 2012 Feb 7.
- Fuchs C.S., Tomasek J.,Yong C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-9. doi: 10.1016/S0140-6736(13)61719-5.
- Wilke H., Muro K., Van Cutsem E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet. Oncol. 2014;15:1224-35. doi: 10.1016/S1470-2045(14)70420-6.